The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer

Ayako Nakashoji, Tetsu Hayashida, Takamichi Yokoe, Hinako Maeda, Tomoka Toyota, Masayuki Kikuchi, Rurina Watanuki, Aiko Nagayama, Tomoko Seki, Maiko Takahashi, Takayuki Abe, Yuukou Kitagawa

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Background We previously described a systematic assessment of the neoadjuvant therapies for human epidermal growth factor receptor-2 (HER2) positive breast cancer, using network meta-analysis. Accumulation of new clinical data has compelled us to update the analysis. Methods Randomized trials comparing different anti-HER2 regimens in the neoadjuvant setting were included, and odds ratio for pathologic complete response (pCR) in seven treatment arms were assessed by pooling effect sizes. Direct and indirect comparisons using a Bayesian statistical model were performed. All statistical tests were two-sided. Results A database search identified 993 articles with 13 studies meeting the eligibility criteria, including three new studies with lapatinib (lpnb). In an indirect comparison, dual anti-HER2 agents with CT achieved a better pCR rate than other arms. The credibility intervals of CT + tzmb + lpnb arm were largely reduced compared to our former report, which we added sufficient clinical evidence by this update. Values of surface under the cumulative ranking (SUCRA) suggested that CT + tzmb + pzmb had the highest probability of being the best treatment arm for pCR, widening the difference between the top two dual-HER2 blockade arms compared to our former report. The overall consistency with our first report enhanced the credibility of the results. Conclusion Network meta-analysis using new clinical data firmly establish that combining two anti-HER2 agents with CT is most effective against HER2-positive breast cancer in the neoadjuvant setting. New pzmb related trials are required to fully determine the best neoadjuvant dual-HER2 blockade regimen.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalCancer Treatment Reviews
Volume62
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Statistical Models
Network Meta-Analysis
human ERBB2 protein
Odds Ratio
Databases
Therapeutics

Keywords

  • Breast cancer
  • Dual-HER2 blockade
  • HER2
  • Human epidermal growth factor receptor-2
  • Neoadjuvant
  • Network meta-analysis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer. / Nakashoji, Ayako; Hayashida, Tetsu; Yokoe, Takamichi; Maeda, Hinako; Toyota, Tomoka; Kikuchi, Masayuki; Watanuki, Rurina; Nagayama, Aiko; Seki, Tomoko; Takahashi, Maiko; Abe, Takayuki; Kitagawa, Yuukou.

In: Cancer Treatment Reviews, Vol. 62, 01.01.2018, p. 9-17.

Research output: Contribution to journalReview article

Nakashoji, Ayako ; Hayashida, Tetsu ; Yokoe, Takamichi ; Maeda, Hinako ; Toyota, Tomoka ; Kikuchi, Masayuki ; Watanuki, Rurina ; Nagayama, Aiko ; Seki, Tomoko ; Takahashi, Maiko ; Abe, Takayuki ; Kitagawa, Yuukou. / The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer. In: Cancer Treatment Reviews. 2018 ; Vol. 62. pp. 9-17.
@article{93cf9269b3634c15baf5d6c0a0ab5dc2,
title = "The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer",
abstract = "Background We previously described a systematic assessment of the neoadjuvant therapies for human epidermal growth factor receptor-2 (HER2) positive breast cancer, using network meta-analysis. Accumulation of new clinical data has compelled us to update the analysis. Methods Randomized trials comparing different anti-HER2 regimens in the neoadjuvant setting were included, and odds ratio for pathologic complete response (pCR) in seven treatment arms were assessed by pooling effect sizes. Direct and indirect comparisons using a Bayesian statistical model were performed. All statistical tests were two-sided. Results A database search identified 993 articles with 13 studies meeting the eligibility criteria, including three new studies with lapatinib (lpnb). In an indirect comparison, dual anti-HER2 agents with CT achieved a better pCR rate than other arms. The credibility intervals of CT + tzmb + lpnb arm were largely reduced compared to our former report, which we added sufficient clinical evidence by this update. Values of surface under the cumulative ranking (SUCRA) suggested that CT + tzmb + pzmb had the highest probability of being the best treatment arm for pCR, widening the difference between the top two dual-HER2 blockade arms compared to our former report. The overall consistency with our first report enhanced the credibility of the results. Conclusion Network meta-analysis using new clinical data firmly establish that combining two anti-HER2 agents with CT is most effective against HER2-positive breast cancer in the neoadjuvant setting. New pzmb related trials are required to fully determine the best neoadjuvant dual-HER2 blockade regimen.",
keywords = "Breast cancer, Dual-HER2 blockade, HER2, Human epidermal growth factor receptor-2, Neoadjuvant, Network meta-analysis",
author = "Ayako Nakashoji and Tetsu Hayashida and Takamichi Yokoe and Hinako Maeda and Tomoka Toyota and Masayuki Kikuchi and Rurina Watanuki and Aiko Nagayama and Tomoko Seki and Maiko Takahashi and Takayuki Abe and Yuukou Kitagawa",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ctrv.2017.10.009",
language = "English",
volume = "62",
pages = "9--17",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer

AU - Nakashoji, Ayako

AU - Hayashida, Tetsu

AU - Yokoe, Takamichi

AU - Maeda, Hinako

AU - Toyota, Tomoka

AU - Kikuchi, Masayuki

AU - Watanuki, Rurina

AU - Nagayama, Aiko

AU - Seki, Tomoko

AU - Takahashi, Maiko

AU - Abe, Takayuki

AU - Kitagawa, Yuukou

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background We previously described a systematic assessment of the neoadjuvant therapies for human epidermal growth factor receptor-2 (HER2) positive breast cancer, using network meta-analysis. Accumulation of new clinical data has compelled us to update the analysis. Methods Randomized trials comparing different anti-HER2 regimens in the neoadjuvant setting were included, and odds ratio for pathologic complete response (pCR) in seven treatment arms were assessed by pooling effect sizes. Direct and indirect comparisons using a Bayesian statistical model were performed. All statistical tests were two-sided. Results A database search identified 993 articles with 13 studies meeting the eligibility criteria, including three new studies with lapatinib (lpnb). In an indirect comparison, dual anti-HER2 agents with CT achieved a better pCR rate than other arms. The credibility intervals of CT + tzmb + lpnb arm were largely reduced compared to our former report, which we added sufficient clinical evidence by this update. Values of surface under the cumulative ranking (SUCRA) suggested that CT + tzmb + pzmb had the highest probability of being the best treatment arm for pCR, widening the difference between the top two dual-HER2 blockade arms compared to our former report. The overall consistency with our first report enhanced the credibility of the results. Conclusion Network meta-analysis using new clinical data firmly establish that combining two anti-HER2 agents with CT is most effective against HER2-positive breast cancer in the neoadjuvant setting. New pzmb related trials are required to fully determine the best neoadjuvant dual-HER2 blockade regimen.

AB - Background We previously described a systematic assessment of the neoadjuvant therapies for human epidermal growth factor receptor-2 (HER2) positive breast cancer, using network meta-analysis. Accumulation of new clinical data has compelled us to update the analysis. Methods Randomized trials comparing different anti-HER2 regimens in the neoadjuvant setting were included, and odds ratio for pathologic complete response (pCR) in seven treatment arms were assessed by pooling effect sizes. Direct and indirect comparisons using a Bayesian statistical model were performed. All statistical tests were two-sided. Results A database search identified 993 articles with 13 studies meeting the eligibility criteria, including three new studies with lapatinib (lpnb). In an indirect comparison, dual anti-HER2 agents with CT achieved a better pCR rate than other arms. The credibility intervals of CT + tzmb + lpnb arm were largely reduced compared to our former report, which we added sufficient clinical evidence by this update. Values of surface under the cumulative ranking (SUCRA) suggested that CT + tzmb + pzmb had the highest probability of being the best treatment arm for pCR, widening the difference between the top two dual-HER2 blockade arms compared to our former report. The overall consistency with our first report enhanced the credibility of the results. Conclusion Network meta-analysis using new clinical data firmly establish that combining two anti-HER2 agents with CT is most effective against HER2-positive breast cancer in the neoadjuvant setting. New pzmb related trials are required to fully determine the best neoadjuvant dual-HER2 blockade regimen.

KW - Breast cancer

KW - Dual-HER2 blockade

KW - HER2

KW - Human epidermal growth factor receptor-2

KW - Neoadjuvant

KW - Network meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=85033369822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033369822&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2017.10.009

DO - 10.1016/j.ctrv.2017.10.009

M3 - Review article

C2 - 29127857

AN - SCOPUS:85033369822

VL - 62

SP - 9

EP - 17

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -